Literature DB >> 19118008

NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A.

Doris Macheiner1, Christine Gauglhofer, Chantal Rodgarkia-Dara, Michael Grusch, Andreas Brachner, Christoph Bichler, Daniela Kandioler, Hedwig Sutterlüty, Wolfgang Mikulits, Rolf Schulte-Hermann, Bettina Grasl-Kraupp.   

Abstract

Recently, we found epigenetic silencing of the Ras effector genes NORE1B and/or RASSF1A in 97% of the hepatocellular carcinoma (HCC) investigated. This is strong evidence that the two genes are of major significance in hepatocarcinogenesis. Although RASSF1A serves as a tumor suppressor gene, the functions of NORE1B are largely unknown. Here, we studied the role of NORE1B for growth and transformation of cells. To understand the molecular mechanisms of action of the gene, we used the wild-type form and deletion mutants without the NH(2) terminus and CENTRAL domain, the Ras association (RA) domain, or the COOH-terminal SARAH-domain. Intact RA and SARAH-domains were found to be necessary for NORE1B (a) to increase the G(0)-G(1) fraction in hepatoma cells, (b) to suppress c-Myc/Ha-Ras-induced cell transformation, and (c) to interact closely with RASSF1A, as determined with fluorescence resonance energy transfer. In further studies, cell cycle delay by NORE1B was equally effective in hepatocyte cell lines with wild-type or mutant Ras suggesting that NORE1B does not interact with either Ras. In conclusion, NORE1B suppresses replication and transformation of cells as effectively as RASSF1A and thus is a putative tumor suppressor gene. NORE1B interacts physically with RASSF1A and functional loss of one of the interacting partners may lead to uncontrolled growth and transformation of hepatocytes. This may explain the frequent epigenetic silencing of NORE1B and/or RASSF1A in HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19118008     DOI: 10.1158/0008-5472.CAN-08-2144

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

Authors:  Bert H O'Neil; Laura W Goff; John Sae Wook Kauh; Jonathan R Strosberg; Tanios S Bekaii-Saab; Ruey-Min Lee; Aslamuzzaman Kazi; Dominic T Moore; Maria Learoyd; Richard M Lush; Said M Sebti; Daniel M Sullivan
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities.

Authors:  Christoph-Erik Mayer; Barbara Haigl; Florian Jantscher; Gerald Siegwart; Michael Grusch; Walter Berger; Hedwig Sutterlüty
Journal:  Cell Mol Life Sci       Date:  2010-05-12       Impact factor: 9.261

3.  RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma.

Authors:  Wei Guo; Cong Wang; Yanli Guo; Supeng Shen; Xin Guo; Gang Kuang; Zhiming Dong
Journal:  Clin Exp Metastasis       Date:  2015-01-13       Impact factor: 5.150

4.  Comparative analysis of interactions of RASSF1-10.

Authors:  Jia Jia Chan; Delphine Flatters; Fernando Rodrigues-Lima; Jun Yan; Konstantinos Thalassinos; Matilda Katan
Journal:  Adv Biol Regul       Date:  2013-01-11

5.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

6.  Aberrant RASSF5 gene transcribed region hypermethylation in pediatric hepatoblastomas.

Authors:  Gongbao Liu; Baihui Liu; Shan Zheng; Kuiran Dong; Rui Dong
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

7.  The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.

Authors:  Anna Djos; Tommy Martinsson; Per Kogner; Helena Carén
Journal:  Mol Cancer       Date:  2012-06-13       Impact factor: 27.401

8.  Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma.

Authors:  Diego F Calvisi; Matthias Evert; Frank Dombrowski
Journal:  Mol Biol Int       Date:  2012-04-02

9.  Circular RNA circRASSF5 Functions as an Anti-Oncogenic Factor in Hepatocellular Carcinoma by Acting as a Competitive Endogenous RNA Through Sponging miR-331-3p.

Authors:  Zhao Zhou; Xiaohan Cui; Peng Gao; Xudong Zhang; Chunfu Zhu; Beicheng Sun
Journal:  J Hepatocell Carcinoma       Date:  2022-10-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.